ATB01

BPI

Native - Human Neutrophils

Alternate Names:

CAP57 | Bactericidal/permeability-increasing protein

Uniprot IDs:
mRNA RefSeq:
Protein RefSeq:

Want to see pricing and place an order?

Register and then log-in

Have an enquiry about this product?

Go here

Product Information

The existence of autoantibodies to bactericidal/permeability-increasing protein (BPI) was first described when it was noticed that 11 of 51 sera that were cANCA positive in immunofluorescence, recognised a 57 kDa antimicrobial cationic protein known as CAP57 in both ELISA and Western blot. It is now known that CAP57 and BPI are identical.

More recently BPI purified from neutrophil granula was used to directly demonstrate the existence of anti-BPI autoantibodies in a range of vasculitic disorders by ELISA and Western blot. BPI-ANCA have since been demonstrated to be present in a range of clinical conditions including ulcerative colitis, Crohn’s disease, cystic fibrosis, rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disease, Behcet’s disease, bronchieactasis, primary sclerosing cholangitis and chronic liver diseases.

BPI is a highly cationic protein that is stored in the azurophil granula of neutrophils. BPI is a potent antibacterial agent with selective toxicity towards Gram-negative bacteria. It binds to the lipopolysaccharides present in the outer envelope of these bacteria to exert immediate bacteriostatic effects and later, bactericidal effects. Analysis of the activity of proteolytic fragments and of the crystal structure of BPI reveal that the protein consists of two functionally distinct domains: a potent antibacterial and anti-endotoxin 20 kDa domain at the amino-terminal and a carboxyl terminal domain that is responsible for BPI’s opsonic activity.

Epitope studies using a panel of recombinant truncated BPI proteins indicate that anti-neutrophil cytoplasmic antibodies to BPI recognise the carboxyl terminal domain. It has also been suggested elsewhere that BPI-ANCA binding sites are likely to be conformational epitopes, as is the case with autoantibodies to proteinase 3 and myeloperoxidase.

Clinical Indications

Primary Sclerosing Cholangitis
Crohn’s Disease
Ulcerative Colitis
Glomerular Diseases

Certificate of Analysis

Please log in to view certificates of analysis for this item

References

  1. Falk, R.J. et al. (1991) Am. J. Kidney Dis. 18, 197 (abstract 6)
  2. Pereira, H.A. et al. (1990) Blood 76, 825
  3. Zhao, M.H. et al. (1995) Clin. Exp. Immunol. 99, 49
  4. Cooper, T. et al. (2000) Rheumatol. Int. 19, 129Aebi, C. et al. (2000) Pediatr. Infect. Dis. J. 19, 207
  5. Burrows, N.P. et al. (1996) J. R. Soc. Med. 89, 47
  6. PFolwaczny C. et al. (1998) Z. Gastroenterol 36, 625
  7. Lindgren, S. et al. (2000) J. Gastroenterol. Hepatol. 15, 437
  8. Locht, H. et al. (2000) Ann. Rheum. Dis. 59, 898
  9. Mahadeva, R. et al. (1999) Clin. Exp. Immunol. 117, 561
  10. Manolova, I. (2001) Rheumatol. Int. 20, 197
  11. Matsuyama, W. et al. (1999) Intern. Med. 38, 813
  12. Roozendaal, C. et al. (1998) Am. J. Med. 105, 393
  13. Schnabel, A. et al. (1997) Med. Klin. 92, 389
  14. Schultz, H. et al. (2000) Pediatr. Allergy Immunol. 11, 64
  15. Sediva, A. et al. (1998) J. Autoimmun. 11, 185
  16. Stoffel, M.P. et al. (1996) Clin. Exp. Immunol. 104, 54
  17. Vecchi, M. et al. (1998) Scan. J. Gastroenterol. 33, 1284
  18. Walmsley, R.S. et al. (1997) Gut 40, 105
  19. Zhao, M.H. et al. QJM (1996) 89, 259
  20. Weiss, J. et al. (1978) J. Biol. Chem. 253, 2664
  21. Weiss, J. & Olsson, I. (1987) Blood 69, 652
  22. Elsbach, P. & Weiss, J. (1993) Immunobiology 187, 417
  23. Mannion, B.A. et al. (1990) J. Clin. Invest. 85, 853
  24. Capodici, C. & Weiss, J. (1996) J. Immunol. 156, 4789
  25. Beamer, L.J. et al. (1997) Science 276, 1861
  26. Dunn, A.C. et al. (1999) J. Infect. 39, 81
  27. Schultz, H. et al. (2000) Pediatr. Allergy Immunol. 11, 64
  28. Schultz, H. et al. (1997) J. Immunol. Methods 205, 127
  29. Schultz, H. et al. (2001) J. Leukocyte Biol. 69, 505

After a custom reagent?

Need to discuss specific protein requirements. Our team can help create tailored solutions to meet your diagnostic needs.